229 related articles for article (PubMed ID: 32764145)
21. The histone H3K79 methyltransferase Dot1L is essential for mammalian development and heterochromatin structure.
Jones B; Su H; Bhat A; Lei H; Bajko J; Hevi S; Baltus GA; Kadam S; Zhai H; Valdez R; Gonzalo S; Zhang Y; Li E; Chen T
PLoS Genet; 2008 Sep; 4(9):e1000190. PubMed ID: 18787701
[TBL] [Abstract][Full Text] [Related]
22. DOT1L inhibits SIRT1-mediated epigenetic silencing to maintain leukemic gene expression in MLL-rearranged leukemia.
Chen CW; Koche RP; Sinha AU; Deshpande AJ; Zhu N; Eng R; Doench JG; Xu H; Chu SH; Qi J; Wang X; Delaney C; Bernt KM; Root DE; Hahn WC; Bradner JE; Armstrong SA
Nat Med; 2015 Apr; 21(4):335-43. PubMed ID: 25822366
[TBL] [Abstract][Full Text] [Related]
23. Methyltransferase Dot1l preferentially promotes innate IL-6 and IFN-β production by mediating H3K79me2/3 methylation in macrophages.
Chen X; Liu X; Zhang Y; Huai W; Zhou Q; Xu S; Chen X; Li N; Cao X
Cell Mol Immunol; 2020 Jan; 17(1):76-84. PubMed ID: 30275539
[TBL] [Abstract][Full Text] [Related]
24. Loss of Histone H3 K79 Methyltransferase Dot1l Facilitates Kidney Fibrosis by Upregulating Endothelin 1 through Histone Deacetylase 2.
Zhang L; Chen L; Gao C; Chen E; Lightle AR; Foulke L; Zhao B; Higgins PJ; Zhang W
J Am Soc Nephrol; 2020 Feb; 31(2):337-349. PubMed ID: 31843983
[TBL] [Abstract][Full Text] [Related]
25. Maturation-related histone modifications in the PU.1 promoter regulate Th9-cell development.
Ramming A; Druzd D; Leipe J; Schulze-Koops H; Skapenko A
Blood; 2012 May; 119(20):4665-74. PubMed ID: 22446486
[TBL] [Abstract][Full Text] [Related]
26. Structural basis of recognition and destabilization of the histone H2B ubiquitinated nucleosome by the DOT1L histone H3 Lys79 methyltransferase.
Jang S; Kang C; Yang HS; Jung T; Hebert H; Chung KY; Kim SJ; Hohng S; Song JJ
Genes Dev; 2019 Jun; 33(11-12):620-625. PubMed ID: 30923167
[TBL] [Abstract][Full Text] [Related]
27. Targeting of histone methyltransferase DOT1L plays a dual role in chemosensitization of retinoblastoma cells and enhances the efficacy of chemotherapy.
Mao Y; Sun Y; Wu Z; Zheng J; Zhang J; Zeng J; Lee C; Kim JK
Cell Death Dis; 2021 Dec; 12(12):1141. PubMed ID: 34887387
[TBL] [Abstract][Full Text] [Related]
28. DOT1L-mediated H3K79 methylation in chromatin is dispensable for Wnt pathway-specific and other intestinal epithelial functions.
Ho LL; Sinha A; Verzi M; Bernt KM; Armstrong SA; Shivdasani RA
Mol Cell Biol; 2013 May; 33(9):1735-45. PubMed ID: 23428873
[TBL] [Abstract][Full Text] [Related]
29. A chemical biology toolbox to study protein methyltransferases and epigenetic signaling.
Scheer S; Ackloo S; Medina TS; Schapira M; Li F; Ward JA; Lewis AM; Northrop JP; Richardson PL; Kaniskan HÜ; Shen Y; Liu J; Smil D; McLeod D; Zepeda-Velazquez CA; Luo M; Jin J; Barsyte-Lovejoy D; Huber KVM; De Carvalho DD; Vedadi M; Zaph C; Brown PJ; Arrowsmith CH
Nat Commun; 2019 Jan; 10(1):19. PubMed ID: 30604761
[TBL] [Abstract][Full Text] [Related]
30. Leukemic transformation by the MLL-AF6 fusion oncogene requires the H3K79 methyltransferase Dot1l.
Deshpande AJ; Chen L; Fazio M; Sinha AU; Bernt KM; Banka D; Dias S; Chang J; Olhava EJ; Daigle SR; Richon VM; Pollock RM; Armstrong SA
Blood; 2013 Mar; 121(13):2533-41. PubMed ID: 23361907
[TBL] [Abstract][Full Text] [Related]
31. DOT1L as a therapeutic target for the treatment of DNMT3A-mutant acute myeloid leukemia.
Rau RE; Rodriguez BA; Luo M; Jeong M; Rosen A; Rogers JH; Campbell CT; Daigle SR; Deng L; Song Y; Sweet S; Chevassut T; Andreeff M; Kornblau SM; Li W; Goodell MA
Blood; 2016 Aug; 128(7):971-81. PubMed ID: 27335278
[TBL] [Abstract][Full Text] [Related]
32. DOT1L modulates the senescence-associated secretory phenotype through epigenetic regulation of IL1A.
Leon KE; Buj R; Lesko E; Dahl ES; Chen CW; Tangudu NK; Imamura-Kawasawa Y; Kossenkov AV; Hobbs RP; Aird KM
J Cell Biol; 2021 Aug; 220(8):. PubMed ID: 34037658
[TBL] [Abstract][Full Text] [Related]
33. Histone methyltransferase DOT1L mediates the TGF-β1/Smad3 signaling pathway through epigenetic modification of SYK in myocardial infarction.
Li F; Li L; Zhang J; Yang X; Liu Y
Hum Cell; 2022 Jan; 35(1):98-110. PubMed ID: 34635982
[TBL] [Abstract][Full Text] [Related]
34. Aqp2-expressing cells give rise to renal intercalated cells.
Wu H; Chen L; Zhou Q; Zhang X; Berger S; Bi J; Lewis DE; Xia Y; Zhang W
J Am Soc Nephrol; 2013 Feb; 24(2):243-52. PubMed ID: 23308014
[TBL] [Abstract][Full Text] [Related]
35. The histone methyltransferase Dot1/DOT1L as a critical regulator of the cell cycle.
Kim W; Choi M; Kim JE
Cell Cycle; 2014; 13(5):726-38. PubMed ID: 24526115
[TBL] [Abstract][Full Text] [Related]
36. DOT1L-mediated murine neuronal differentiation associates with H3K79me2 accumulation and preserves SOX2-enhancer accessibility.
Ferrari F; Arrigoni L; Franz H; Izzo A; Butenko L; Trompouki E; Vogel T; Manke T
Nat Commun; 2020 Oct; 11(1):5200. PubMed ID: 33060580
[TBL] [Abstract][Full Text] [Related]
37. DOT1L/KMT4 recruitment and H3K79 methylation are ubiquitously coupled with gene transcription in mammalian cells.
Steger DJ; Lefterova MI; Ying L; Stonestrom AJ; Schupp M; Zhuo D; Vakoc AL; Kim JE; Chen J; Lazar MA; Blobel GA; Vakoc CR
Mol Cell Biol; 2008 Apr; 28(8):2825-39. PubMed ID: 18285465
[TBL] [Abstract][Full Text] [Related]
38. Histone monoubiquitylation position determines specificity and direction of enzymatic cross-talk with histone methyltransferases Dot1L and PRC2.
Whitcomb SJ; Fierz B; McGinty RK; Holt M; Ito T; Muir TW; Allis CD
J Biol Chem; 2012 Jul; 287(28):23718-25. PubMed ID: 22619169
[TBL] [Abstract][Full Text] [Related]
39. Epigenetic Reprogramming of Lineage-Committed Human Mammary Epithelial Cells Requires DNMT3A and Loss of DOT1L.
Breindel JL; Skibinski A; Sedic M; Wronski-Campos A; Zhou W; Keller PJ; Mills J; Bradner J; Onder T; Kuperwasser C
Stem Cell Reports; 2017 Sep; 9(3):943-955. PubMed ID: 28781076
[TBL] [Abstract][Full Text] [Related]
40. DOT1L affects colorectal carcinogenesis via altering T cell subsets and oncogenic pathway.
Sun D; Wang W; Guo F; Pitter MR; Du W; Wei S; Grove S; Vatan L; Chen Y; Kryczek I; Fearon ER; Fang JY; Zou W
Oncoimmunology; 2022; 11(1):2052640. PubMed ID: 35309733
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
